Revolutionary Diabetes Management – Biosensor Accurately Measures Glucose in Saliva

The world’s first non-invasive, saliva-based glucose test for diabetes management.

Image: The iQ Group Global

The iQ Group Global, an Australian consortium of life science and financial services companies, developed a biosensor capable of accurately measuring glucose in a person’s saliva.

This groundbreaking technology is the world’s first non-invasive, saliva-based glucose test for diabetes management that measures glucose in saliva rather than blood. The saliva-based glucose test is being developed to improve the quality of life for over 425 million people living with diabetes globally.

Read more Researchers Create 3-D Printed Glucose Biosensor for Wearable Monitors

The technology, invented by Professor Paul Dastoor and his team at the Centre of Organic Electronics at the University of Newcastle in Australia, comprises the Glucose Biosensor Unit and a digital healthcare app. The iQ Group Global acquired the biosensor technology in 2016 and has accelerated its development for diagnostic applications. The Glucose Biosensor Unit is a small, disposable strip, which when exposed to an individual’s saliva instantly provides a glucose measurement. The glucose measurement will be presented in real-time, via a proprietary digital app on a patient’s smart device, said a press release.

“Diabetes is a global epidemic, with 1 in 11 adults living with the disease. Achieving normoglycemia is one of the main targets for diabetes patients. However, finger prick testing is a painful and frustrating process, with many citing the pain as the main reason for poor adherence to testing protocols. By eradicating the need for finger prick blood tests, the saliva-based test will lead to increased glucose monitoring and better healthcare outcomes among these patients,” says Dr. George Syrmalis, Chief Executive Officer and Chairman of The iQ Group Global.

The Glucose Biosensor Unit

The patent protected modified organic thin film transistors work in combination with Glucose Oxidase (GOX) to initiate an electrochemical reaction that produces an electrical signal. This signal can be displayed on the patient’s smart device in real time. Due to its high sensitivity the biosensor can detect glucose levels at considerably lower levels than in blood. It has a linear glucose sensing capability at concentrations of 100 times lower than current blood measuring methodologies.

Read more VitalConnect’s VitalPatch Biosensor and VistaTablet Provides Continuous Patient Monitoring Anywhere

Future Medical Applications

The iQ Group Global is currently working on a pilot research and development program with the University of Newcastle to expand beyond the saliva glucose diagnostic test and develop the platform of Point of Care Diagnostic Tests beginning with tumor markers, hormones, and communicable diseases.

Sam Draper
February 6, 2019

Innovation of the Month

Do you want to discover more, visit the website
Visit Website

Other news

Huawei Launches Digital Medical Technology Solution

Huawei’s Digital Medical Technology Solution is based on cloud computing, big data, and AI.

Fertility Tracking App Flo Raises $50M Series B Round, Bringing Company Valuation to $800M

Fertility tracking app Flo announced it closed $50M in a Series B financing, bringing the total ...

Wearable Freeze-Dried Cell-Free Face Masks for COVID-19 Detection

Integrating synthetic biology into wearables could expand opportunities for noninvasive ...

Tracking Sleep with a Self-Powering Smart Pillow

Development of a self-powering smart pillow that tracks sleep by tracking the position of the head.
Discover more